

DOCTORAL THESIS

Studies on the quality control and pharmacokinetics of QFGJS capsule, an anti-arthritic Chinese herbal preparation

Xie, Ying

Date of Award:
2007

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

**Studies on the Quality Control and Pharmacokinetics of QFGJS
Capsule, an Anti-Arthritic Chinese Herbal Preparation**

XIE Ying

A thesis submitted in partial fulfillment of the requirements

for the degree of

Doctor of Philosophy

Principal Supervisor: Prof. LIU Liang

Hong Kong Baptist University

November 2007

ABSTRACT

Interests and applications of herbal medicinal products (HMPs) have been markedly increased worldwide in the past decades, as HMPs demonstrated great potential for treatment of complicated diseases and for improvement of health. Qingfu Guanjiesshu (QFGJS) capsule derived from five well-documented herbs is developed for treating human rheumatoid arthritis. Previous studies conducted by our research group showed that QFGJS had significant anti-arthritic, anti-inflammatory and analgesic effects. Those effects depend on a reproducible and consistent quality of the products. Thus, establishment of quality control methods and standard of QFGJS is a key issue for safe and effective clinical usage of the product. However, due to the chemical complexity and the potential interactions among chemicals and trace concentrations of analytes, studies on systematic quality control of HMPs are particularly difficult. The current work aims to develop methods for ensuring the quality and safety of QFGJS, which includes a series of quantitative and qualitative chemical analyses, and pharmacokinetic studies.

The processed aconite (*Ranunculaceae*) root, one of the five herbs in the formula of QFGJS, is widely used to treat joint pain and arthritic diseases, but contains toxic *Aconitum* alkaloids, i.e., aconitine, mesaconitine, and hypaconitine. To control the quality of the processed aconite roots for ensuring safe usage of QFGJS, a sensitive HPLC method was developed for determining those alkaloids by using a C₁₈ column gradient eluted with acetonitrile and 10mM ammonium bicarbonate buffer. The results showed that contents of those toxic alkaloids in different batches of the herbal samples varied significantly. Moreover, for HMPs containing aconite roots, a modified HPLC method was developed for simultaneous determination of six *Aconitum* alkaloids, i.e., three toxic alkaloids and their corresponding hydrolyzed products. The results showed that the contents of all six alkaloids in twelve Chinese proprietary products containing aconite roots varied markedly. This developed method has provided a technical platform to manufacturers for controlling the content limits of those toxic alkaloids in HMPs. By using this modified HPLC method to determine toxic *Aconitum* alkaloids in QFGJS, only trace contents are observed, which are within the limits stipulated by Chinese Pharmacopoeia, suggesting good safety of QFGJS in clinical use.

In order to evaluate the quality consistency of QFGJS from batch-to-batch and its stability after production, an HPLC-DAD method for quantitative and qualitative analysis of QFGJS was established. Simultaneous determination of four marker compounds, i.e., sinomenine, paeoniflorin, paeonol, and curcumin in QFGJS, was conducted by using this method. Qualitative chromatographic fingerprint analysis of QFGJS was carried out at the same time, showing the chemical characteristics of the four out of five herbs in the herbal formula (except the processed aconite roots) of QFGJS in the HPLC fingerprint chromatograms. This comprehensive HPLC analytical evaluation showed that both the contents of four marker compounds and the HPLC fingerprint profiles were consistent in all three batches of QFGJS products and also almost unchangeable in samples subject to the stability tests, which indicates that the quality of QFGJS was reproducible and consistent in the manufacturing processes. In this study, the way to develop an HPLC method providing both quantitative determination and qualitative fingerprint analysis as well as conducting methodology validation was investigated, which would be useful for quality assessment of other HMPs.

To evaluate the bioavailability of QFGJS, pharmacokinetic studies were carried out through investigating the concentration time course of bioactive compounds and metabolites. By using the developed sensitive HPLC methods, plasma concentrations of sinomenine, paeoniflorin, and paeonol were successfully determined after oral administration of QFGJS in the jugular-catheterized moving rats. It was found that three compounds were absorbed into blood, but their pharmacokinetic behaviors were different from those of the pure compounds described in the references. To further investigate the differences in the pharmacokinetic behavior of paeonol in QFGJS, the plasma concentrations of paeonol were determined after oral administration of pure paeonol and QFGJS. The results showed that both the plasma concentration and AUC of paeonol were significantly elevated in rats treated with QFGJS compared with those treated with pure paeonol at a comparable dosage, while the T_{max} , $T_{1/2}$, and MRT were showed to be similar in two groups. Moreover, the concentrations of four metabolites of paeonol detected by using LC-ESI-Q/TOF/MS were found to be higher in rat plasma treated with QFGJS, indicating that the increased concentration of paeonol in plasma did not result from the inhibition of metabolism. Thus, those differences in pharmacokinetics of paeonol might be caused by other co-existing chemicals in QFGJS.

To investigate whether there are cross-influences among the chemicals in QFGJS on toxicity, aconitine and paeoniflorin were employed for the study. The preliminary results showed that paeoniflorin could markedly increase the value of LD_{50} of aconitine and reduce the death ratio of mice caused by orally taking aconitine. By using a cardiac arrhythmia model induced by aconitine on rat right atria to further investigate the possible detoxifying mechanisms of paeoniflorin, the results showed that paeoniflorin could significantly inhibit cardiac arrhythmias caused by aconitine, which indicates that the detoxifying effect of paeoniflorin could be derived from chemical-chemical interactions in QFGJS.

In summary, a comprehensive quality control system has been successfully established for ensuring the quality and safety of QFGJS in this thesis, in which the chemical analytical method, chromatographic fingerprint analysis, pharmacokinetic study and toxicological test have been taken into account.

TABLE OF CONTENTS

DECLARATION.....	i
ABSTRACT.....	ii
ACKNOWLEDGEMENTS.....	iv
TABLE OF CONTENTS.....	vi
LIST OF TABLES.....	xiv
LIST OF FIGURES.....	xvii
LIST OF ABBREVIATIONS.....	xxi

PART I INTRODUCTION ON THE QUALITY CONTROL RESEARCH OF

HERBAL MEDICINAL PRODUCTS.....	1
1. The Needs, Ways and Methods for Quality Control Research of Herbal Medicinal Products (HMPs).....	2
1.1 General background of HMPs	2
1.2 The characteristics of HMPs.....	3
1.3 The need on the research of quality control methods for HMPs.....	6
1.4 The way for quality control of HMPs.....	10
1.4.1 Quality control of the raw materials.....	10
1.4.2 Quality control of the drug substances or extracts of HMPs.....	12
1.4.3 Assurance of the stability of HMPs.....	15
1.4.4 Quality control study by using pharmacokinetic information.....	16
1.5 Methods and technologies for quality control of HMPs.....	18
1.5.1 Extraction method and samples preparation.....	19

1.5.2 Chromatographic analysis methods.....	21
1.5.3 Combinative methods of chromatography and mass spectrometry.....	25
1.5.4 Chromatographic fingerprint analysis.....	27
1.5.5 Pharmacokinetic study of HMPs	31
2. Background of a Novel Anti-arthritic Herbal Preparation, QFGJS Capsule	33
2.1 The need of HMPs for the treatment of RA	33
2.2 Rationale of the composition of QFGJS formula	33
2.3 Pharmaceutical extraction and pilot manufacturing of QFGJS	37
2.4 General studies on toxicity of the pilot products of QFGJS	39
2.5 Anti-arthritic effect of QFGJS.....	40
3. Aims, Objectives and Methodologies of the Research.....	42
3.1 Aims and objectives	42
3.2 Outlines in experimental design and methodologies relevant to the research....	45
PART II METHOD DEVELOPMENT FOR QUALITY CONTROL AND	
STABILITY TEST OF QFGJS CAPSULE.....	48
Preface for Part II.....	49
Chapter 1 Quantitative Determination of Toxic <i>Aconitum</i> Alkaloids in Aconite	
Roots	50
1 Introduction.....	50
2 Experimental.....	52
2.1 Chemicals and reagents.....	52
2.2 Medicinal materials and preparation of sample solutions	53

2.3	Extraction protocols.....	54
2.4	Preparation of standard solutions and calibration.....	55
2.5	Chromatographic analysis.....	56
2.6	Validation of <i>Aconitum</i> alkaloids quantification method	56
3	Results.....	57
3.1	Optimization of the extraction conditions.....	57
3.2	Optimization of the chromatographic conditions.....	58
3.3	Validation of <i>Aconitum</i> alkaloids quantification method.....	60
3.4	Quantitative determination of the <i>Aconitum</i> alkaloids in medicinal materials..	61
4	Discussions.....	64
Chapter 2 Simultaneous Determination of Six <i>Aconitum</i> Alkaloids in Herbal		
Medicinal Products by HPLC Method.....		
1	Introduction.....	67
2	Experimental.....	70
2.1	Sources of the raw materials and Chinese proprietary products.....	70
2.2	Chemicals and reagents.....	71
2.3	Chromatographic system.....	72
2.4	Preparation of sample solutions.....	73
2.5	Preparation of standard solutions.....	73
2.6	Validation of the chromatographic method.....	74
3	Results and Discussions.....	74
3.1	Effects of pH value in the mobile phase buffer on the retention time.....	74
3.2	Effects of the mobile phase buffer concentration.....	75

3.3	Extraction conditions.....	77
3.4	Validation of HPLC assay.....	78
3.5	Application of the HPLC method for quantification of six alkaloids in Chinese proprietary products.....	81
4	Conclusions.....	84
Chapter 3 Combinative Method Using HPLC Quantitative and Qualitative Analyses for Assessment of Quality Consistency of QFGJS.....		
1	Introduction.....	89
2	Experimental.....	91
2.1	Chemicals and reagents.....	91
2.2	Raw materials and manufacturing procedures of QFGJS pilot products.....	93
2.3	Samples solutions and negative control (NC) samples preparation.....	94
2.4	Standard solutions preparation.....	95
2.5	Apparatus and chromatographic conditions.....	95
2.6	Validation of HPLC method.....	96
2.7	Similarity calculation of the HPLC fingerprint chromatograms.....	96
3	Results and Discussions.....	97
3.1	Optimization of extraction conditions.....	97
3.2	Optimization of HPLC chromatographic conditions.....	98
3.3	Method validation for quantitative determination of four marker compounds...100	
3.4	Method validation for HPLC fingerprint method.....	102
3.5	Quantitative determination of the marker compounds in QFGJS.....	103
3.6	Attribution of the characteristic peaks from individual herbs.....	107

3.7 Analysis of the stability and consistency of QFGJS products by HPLC fingerprint technology.....	112
4 Conclusions.....	113
PART III PHARMACOKINETIC STUDIES OF QFGJS CAPSULE	115
Preface for Part III.....	116
Chapter 1 Pharmacokinetic Studies of the Bioactive Compounds in Rat Plasma after Oral Administration of QFGJS Capsule	117
1 Introduction.....	117
2 Experimental.....	120
2.1 Chemicals.....	120
2.2 HPLC conditions.....	120
2.3 Animals and surgery.....	121
2.4 Drug administration and blood sampling.....	122
2.5 Preparation of plasma samples.....	123
2.6 Calibration curve.....	123
2.7 Accuracy, precision and recovery tests.....	124
2.8 Stability test.....	124
2.9 Pharmacokinetic analysis.....	125
3 Results.....	125
3.1 Optimization of the chromatographic conditions.....	125
3.2 Calibration curve.....	126
3.3 Accuracy and precision of HPLC method.....	128
3.4 Recovery rate of HPLC method.....	129

3.5 Stability.....	130
3.6 Pharmacokinetics of SI, PF and PA.....	131
4 Discussions.....	135
Chapter 2 A Comparative Study on the Pharmacokinetic Behavior and Metabolism	
of Paeonol in Rats Orally Administrated with the Pure Paeonol Alone	
and QFGJS capsule.....	
1 Introduction.....	139
2 Experimental	142
2.1 Chemicals and reagents.....	142
2.2 HPLC and HPLC-MS conditions.....	142
2.3 Animals and surgery.....	143
2.4 Drug administration and blood sampling.....	143
2.5 Preparation of sample solution.....	144
2.6 Calibration curve.....	145
2.7 Accuracy and precision tests.....	145
2.8 Recovery test.....	146
2.9 Stability test on plasma samples.....	146
2.10 Pharmacokinetic behavior and metabolites determination of paeonol	
in plasma.....	147
3 Results.....	147
3.1 Optimization of HPLC chromatographic conditions and measurement	
of paeonol in rat plasma.....	147
3.2 Calibration curve.....	148

3.3 Accuracy and precision of HPLC method.....	149
3.4 Recovery rate of HPLC method.....	150
3.5 Stability test of paeonol in rat plasma samples.....	151
3.6 Pharmacokinetic behavior of paeonol in rat plasma.....	152
3.7 Metabolic profile of paeonol in rat plasma.....	155
4 Discussions.....	160

PART IV A PRELIMINARY STUDY OF THE INFLUENCES OF
PAEONIFLORIN ON THE ACUTE TOXICITY OF ACONITINE ...164

1. Introduction.....	165
2. Materials and Methods.....	168
2.1 Chemicals	168
2.2 Animals.....	168
2.3 Acute oral toxicity test.....	169
2.4 Study of death ratio of aconitine and co-administration of paeoniflorin.....	169
2.5 Isolated rat atria preparation.....	170
2.6 Anti-arrhythmia experimental protocol.....	170
2.7 Statistical analysis.....	171
3. Results.....	171
3.1 LD50 and death ratios of aconitine and the possible detoxifying effect of paeoniflorin to aconitine	171
3.2 Cardiac arrhythmia model induced by aconitine on the rat right atria and the effect of paeoniflorin.....	172
4. Discussions.....	178

PART V SUMMARY AND PROSPECT OF THE RESEARCH.....	182
1. Summary and Conclusions.....	183
2. Prospect for Further Studies.....	193
REFERENCES.....	196
PUBLICATIONS.....	214
PRESENTATIONS AND ABSTRACTS.....	216
CURRICULUM VITAE.....	217